Can inflammation related diseases increase risk of primary acquired nasolacrimal duct obstruction?
Primary Acquired Nasolacrimal Duct Obstruction (PANDO) has long been a concern for patients, impacting their ocular health. A recent retrospective case-control study conducted by Clalit Health Services in Israel delves into the intricate associations between PANDO and various inflammatory conditions. The findings shed light on the multifaceted nature of PANDO, revealing significant connections with ocular surface, eyelid, upper airway, and systemic inflammatory-related diseases.
This study was published in the journal Graefe's Archive for Clinical and Experimental Ophthalmology by Kerber and colleagues. To evaluate the incidence and risk factors for inflammatory conditions among patients with PANDO. 60,726 patients diagnosed with PANDO, with an average age of 63 years, 63% female. A case-control approach matching controls according to year of birth, sex, and ethnicity.
The key findings of the study were:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.